Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 7/20 | 0.67 |
| ▸ | CA9 | Q16790 | 12/20 | 0.60 |
| ▸ | CA2 | P00918 | 11/20 | 0.60 |
| ▸ | CA12 | O43570 | 8/20 | 0.60 |
| ▸ | CA1 | P00915 | 8/20 | 0.60 |
| ▸ | KIF11 | P52732 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4618138 | 0.84 | S1PR1 (0.70) | S1PR1CA9CA2CA12CA1 | |
| SCHEMBL4618798 | 0.81 | PTGS2 (0.67) | S1PR1KIF11 | |
| SCHEMBL3274472 | 0.80 | S1PR1 (0.51) | S1PR1 | |
| SCHEMBL20615395 | 0.80 | S1PR1 (1.00) | S1PR1 | |
| SCHEMBL4930133 | 0.80 | S1PR1 (0.69) | S1PR1CA9CA2CA12CA1 | |
| SCHEMBL13417113 | 0.78 | S1PR1 (0.75) | S1PR1CA9CA2CA12CA1 | |
| SCHEMBL2809619 | 0.75 | S1PR1 (0.67) | S1PR1CA9CA2CA12CA1 | |
| SCHEMBL6733221 | 0.75 | PTGS2 (0.65) | KIF11 | |
| SCHEMBL20968251 | 0.75 | CA9 (0.63) | S1PR1CA9CA2CA12CA1 | |
| SCHEMBL3562617 | 0.74 | S1PR1 (0.57) | S1PR1CA9CA2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306124-A1 | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands | NOVARTIS AG (CH) | 2008-12-11 | — | — | US | disclosed |
| EP-1893591-A1 | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS | Novartis AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006131336-A1 | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306124-A1 | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands | SOX18, SIGMAR1, SUCNR1 | S1PR1 13/4885CA9 2327/4885CA2 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.